Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated with a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry
{{output}}
Interleukin 12/23 inhibitors (IL-12/23i) and interleukin 17 and 23 inhibitors (IL-17i and IL-23i) represent the drug classes with the most favorable expectations for therapeutic response. However, the introduction of biosimilars has led many centers, for reaso... ...
